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a b s t r a c t
Human Pegivirus (HPgV, formally GB virus C) infects lymphocytes and NK cells in vivo, and infection is
associated with reduced T cell and NK cell activation in HIV-infected individuals. The mechanism by which
HPgV inhibits NK cell activation has not been assessed. Following IL-12 stimulation, IFNγ expression was
lower in HIV-HPgV co-infected subjects compared to HIV mono-infected subjects (p¼0.02). In addition,
HPgV positive human sera, extracellular vesicles containing E2 protein, recombinant E2 protein and
synthetic E2 peptides containing a predicted Tyk2 interacting motif inhibited NK cell IL-12-mediated IFNγ
release. E2 protein also inhibited Tyk2 activation following IL-12 stimulation. In contrast, cytolytic NK cell
function was not altered by HPgV. Inhibition of NK cell-induced proinﬂammatory/antiviral cytokines may
contribute to both HPgV persistence and reduced immune activation during HIV-coinfection. Under-
standing mechanisms by which HPgV alters immune activation may contribute towards novel immuno-
modulatory therapies to treat HIV and inﬂammatory diseases.
Published by Elsevier Inc.
Introduction
Human Pegivirus (HPgV), formerly called hepatitis G virus/GB
virus C (GBV-C), is an RNA virus classiﬁed within the newly
assigned Pegivirus genus of the Flaviviridae (Stapleton et al.,
2012; Adams et al., 2013). Both HPgV and the phylogenetically
related hepatitis C virus (HCV) can establish persistent human
infection through complex mechanisms that are not completely
characterized (Gutierrez et al., 1997; Tanaka et al., 1998; Williams
et al., 2004; Burke and Cox, 2010; Lemon, 2010). In HIV-infected
humans, persistent HPgV coinfection is associated with reduced T
cell activation, proliferation and function (Maidana-Giret et al.,
2009; Schwarze-Zander et al., 2010; Stapleton et al., 2012, 2009)
suggesting that HPgV-mediated immune modulation may contri-
bute to viral persistence. In vitro, HPgV envelope glycoprotein (E2)
inhibits T cell activation by reducing signaling through the IL-2
receptor and the T cell receptor (TCR), with resultant reduction in
activation of the lymphocyte speciﬁc tyrosine kinase (Lck)
(Bhattarai et al., 2013). The effects of HPgV on T cell activation
may contribute to the observed protective effect of HPgV co-
infection on survival of HIV- and Ebola-infected individuals
(Nunnari et al., 2003; Tillmann et al., 2001; Vahidnia et al., 2012;
Xiang et al., 2001; Lauck et al., 2015).
HPgV replicates in peripheral blood mononuclear cells (PBMC)
ex vivo, but the primary type of cell(s) that support HPgV
replication in vivo are not well characterized (Chivero and
Stapleton, 2015). Among chronically infected individuals, HPgV
RNA is found in multiple blood cell types including T and B
lymphocytes, monocytes and natural killer (NK) cells (Chivero
et al., 2014; George et al., 2006). The proportion of cells infected
with HPgV is low (approximately 1–10 genome copies per 100 NK
cells)(Chivero et al., 2014). The majority of serum-derived HPgV
RNA is present in gradient fractions containing extracellular
vesicles (EV) that have properties of exosomes (Bhattarai et al.,
2013; Chivero et al., 2014). It is difﬁcult if not impossible to exclude
the presence of virions from EV preparations; however, HPgV
RNA-containing particles prepared from gradients enriched for
EVs deliver viral RNA to peripheral blood mononuclear cells,
including NK cells (Bhattarai et al., 2013; Chivero et al., 2014).
Natural killer cells serve as rheostats modulating antiviral T cells
(Waggoner et al., 2012; Welsh and Waggoner, 2013). NK cells
eliminate activated CD4þ T cells that normally help CD8þ T-cell
function. In the absence of CD4þ T cell help and an abundance of
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viral antigen, T cell exhaustion may occur. During high titer lympho-
cytic choriomeningitis virus (LCMV) infection, NK cells prevent fatal
pathology while enabling T-cell exhaustion and viral persistence;
however, at lower titer LCMV infection, NK cells paradoxically
facilitate lethal T-cell-mediated pathology. Thus, NK cells regulate
T-cell-mediated responses required for viral control, pathogenesis
and persistence (Waggoner et al., 2012; Welsh and Waggoner, 2013).
HPgV infection frequently persists in humans at high viral concen-
trations, yet the cellular activation marker CD69 is signiﬁcantly lower
on CD56þ bright NK cells in HPgV-HIV co-infected people compared
to those with HIV mono-infection (Stapleton et al., 2013). Thus, HPgV
infection may modulate NK cell activation. In a recent study, HPgV
infection acquired by blood transfusion reduced the plasma concen-
tration of 27 cytokines and chemokines over a 300 days period of
observation. Among those down-modulated, 12 were pro-
inﬂammatory cytokines (GM-CSF, interferon γ (IFN-γ), IFN-α2, inter-
leukin 12p40, interleukin 12p70 (IL-12p70), interleukin 15, interleu-
kin 1α (IL-1α), interleukin 2 (IL-2), IL-7, IL-8, TNF-α, and IL-6,
suggesting an overall antiinﬂammatory effect of HPgV in HIV-
positive subjects (Lanteri et al., 2014). The speciﬁc cell types produ-
cing these cytokines were not identiﬁed. Since HPgV RNA is found in
NK cells and is associated with reduced NK cell activation in HIV-
infected individuals, and because NK cells regulate antiviral T cells
through both direct cytotoxicity and production of cytokines and
chemokines, we hypothesized that HPgV infection may modulate NK
cell function. Consequently, we investigated the effect of HPgV
infection and HPgV particles on NK cell function.
Results
Patient demographics
PBMCs obtained from 26 HIV-infected subjects (5 female, 21
male) were studied. Eleven were HPgV viremic and 15 did not
have HPgV viremia. All subjects were receiving cART and had
undetectable HIV viral load (o48 copies/ml plasma) for Z6
months. In the viremic subjects the average HPgV plasma VL was
4.7107 genome equivalent (GE) per ml of serum. The age, race,
gender and mode of HIV transmission are shown in Table 1.
HPgV infection prolongs NK cell survival and inhibits IL-12 signaling
ex vivo
HPgV infection reduces T cell activation and protects T cells from
activation induced death following stimulation with phytohemag-
glutinin (PHA) and IL-2 (Rydze et al., 2012; Bhattarai et al., 2012).
Since HPgV also infects NK cells (Chivero et al., 2014), the effect of
HPgV infection on primary human NK cell survival following
stimulation was studied. PBMCs from HPgV positive and negative
subjects, both groups with undetectable HIV VL, were stimulated
with PHA/IL-2 and maintained in culture for eight weeks. Essen-
tially no NK cells obtained from HPgV RNA negative subjects were
viable after 21 days in culture; while all NK cells obtained from
HPgV viremic individuals were viable in culture on day 42 (Fig. 1A).
Thus, primary human NK cell survival was signiﬁcantly prolonged
when maintained in PHA/IL-2, suggesting reduced responsiveness
to activation stimulus. Since IL-12 is required to stimulate NK cells
to produce interferon gamma (IFNγ) (Biron and Gazzinelli, 1995;
Romani et al., 1997) and acquisition of HPgV reduces production of
several cytokines including IFNγ (Lanteri et al., 2014), we hypothe-
sized that NK cells from HPgV infected subjects have suppressed
responses to cytokine stimuli such as IL-12, although reduced IL-12
receptors on the NK cells could contribute to these ﬁndings.
To determine if HPgV altered NK cell function, IL-12 induced
IFNγ expression was studied. Several pathogens induce IL-12 which
in turn elicits IFNγ induction by NK cells (Biron and Gazzinelli, 1995;
Romani et al., 1997). IFNγ has antimicrobial and immunoregularory
functions critical to host protection and viral clearance (Gattoni
et al., 2006; Boehm et al., 1997). PBMCs from HIV infected subjects
Table 1
Characteristics of subjects studied.
ID Age yrs Gender Race/Ethicity HIV transmission CD4 HPgV VL HIV VL
1 33 F AA Het 1034 ND o48
2 29 F C/His Het 692 ND o48
3 59 M C MSM 415 ND o48
4 56 M C Het 871 ND o48
5 30 F C Het 819 ND o48
6 42 M C MSM 748 ND o48
7 47 M C/H MSM 819 ND o48
8 49 M C MSM 549 ND o48
9 58 M C MSM 733 ND o48
10 55 M C MSM 441 ND o48
11 52 M C MSM 980 ND o48
12 54 M C MSM 683 ND o48
13 56 M C MSM 650 ND o48
14 44 F AA Het 646 ND o48
15 58 M C MSM 436 ND o48
16 37 M C MSM 437 7.19Eþ07 o48
17 53 M C MSM 1257 9.28Eþ07 o48
18 28 F C HET 791 5.68Eþ07 o48
19 50 M C MSM 778 2.01Eþ08 o48
20 62 M C MSM 134 5.82Eþ07 o48
21 40 M C IDU 307 1.27Eþ07 o48
22 47 M C MSM 793 3.46Eþ06 o48
23 54 M C MSM 1404 2.54Eþ04 o48
24 54 M C MSM 508 7.41Eþ06 o48
25 50 M C MSM 504 1.21Eþ07 o48
26 63 M C MSM 217 1.79Eþ06 o48
ID¼subject identiﬁcation code; CD4¼absolute CD4þ cells/mm3; VL¼viral load in RNA copies/ml; transmission category¼het: heterosexual transmission, MSM: men
having sex with men; IDU: intravenous drug use.
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with 46 months suppressed HIV VL were stimulated with IL-12
and IL-15, and IFNγ was assessed by ﬂow cytometry. NK cells
obtained from HPgV infected subjects had signiﬁcantly reduced
IFNγ expression compared to the HPgV negative subjects (Fig. 1B).
Repeat analysis using a 1%, 2% and 5% positive gating strategy
conﬁrmed that there were signiﬁcant differences between the HPgV
viremic and nonviremic subjects regardless of initial gating (data
not shown). Furthermore, primary NK cells incubated with HPgV
positive sera had signiﬁcantly lower IL-12 mediated IFNγ compared
to cells incubated in HPgV negative sera (Fig. 1C). Sera used in both
treatments and controls were from HIV-infected subjects receiving
cART. All subjects had undetectable HIV VL for 46 months, thus
making serum factors or antiretroviral drug effects unlikely to
inﬂuence the results. HPgV inhibition of IL-2-mediated IFN-γ
production by NK cells did not require HPgV replication, as UV-
treated, replication deﬁcient HPgV particles also inhibited IL-12
induced IFN-γ release by human PBMCs (Fig. 1D). This inhibition of
IFNγ secretion was speciﬁc to the IL-12 pathway, as stimulation of
PBMCs with PMA and ionomycin (bypassing the IL-12 receptor)
rescued IFNγ secretion by HPgV infected primary NK cells. Repre-
sentative subject data are shown in Fig. 2). Together, these data
suggest that serum-derived HPgV particles can suppress IL-12
receptor (IL-12 R)-mediated NK cell function.
HPgV envelope protein (E2) inhibits IL-12 signaling pathways in NK
cells
HPgV envelope protein (E2) modulates TCR and IL-2 receptor
signaling pathways (Bhattarai et al., 2013, 2012). Since HPgV-
mediated inhibition of IL-12 signaling in NK cells did not require
viral replication (Fig. 1D) and HPgV E2 protein is predicted to be
the major surface protein on virions (Mohr and Stapleton, 2009),
the effect of HPgV envelope protein E2 on IL-12 pathway signaling
was assessed. Recombinant Fc-fusion HPgV E2 protein inhibited
IL-12 mediated IFNγ release from NK92 cells compared to cells
incubated with the Fc control protein (Fig. 3 A). Thus, incubation of
HPgV E2 protein was sufﬁcient to modulate IL-12 signaling by NK
92 cells. Extracellular vesicles (EVs) were puriﬁed from cell culture
supernatant ﬂuids of CHO cells as described in the methods
section. EVs expressing E2-Fc contained HPgV E2 protein in
immunoblots, while EVs puriﬁed from CHO cell supernatants
expressing Fc without E2 protein did not (Fig. 3B). Incubation of
NK92 cells with the E2-Fc EVs resulted in the uptake of HPgV E2
protein (Fig. 3C). Fig. 4 shows the gating strategy used to quantify
E2 in NK92 cells. Similarly, incubation of primary human NK cells
with E2-Fc-containing EVs demonstrated uptake of E2 (Fig. 5).
In addition to containing HPgV E2 protein (Fig. 3B), the
Fig. 1. HPgV infection prolongs NK cell survival and inhibits IL-12-induced interferon gamma expression by NK cells. Peripheral blood mononuclear cells (PBMCs) from HPgV
positive subjects (n¼11) and HPgV negative subjects (n¼6) were stimulated with PHA/IL-2 and maintained in culture for eight weeks NK cells obtained from HPgV viremic
subjects survived signiﬁcantly longer than HPgV RNA negative subjects ex vivo (po0.01, chi square) (A). PBMCs from HPgV positive subjects (n¼9) and HPgV negative
subjects (n¼9) were studied for induction of IL12-induced interferon gamma. NK cells obtained from HPgV positive subjects had signiﬁcantly less intracellular IFNγ
expression following IL-12 and IL-15 stimulation (B). Similarly, IFNγ release by the human NK cell line NK92MI following stimulation with IL-12 for 18 h was signiﬁcantly
lower when incubated with HPgV positive human sera (n¼9) compared to HPgV negative sera (n¼9) (C). Ultraviolet inactivation of serum HPgV particles did not alter the
effect of HPgV serum on IFNγ release (D). Data in panel C represent two independent experiments each using three different donors per experiment. P values represent T test
results between groups.
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puriﬁed EVs contained CD63 and CD81 (Fig. 6A and B) but not
CD69 (Fig. 6). Since exosomes have not been reported to contain
CD69, but commonly contain CD63 and CD81, these ﬁndings are
consistent with the EVs being exosomes (http://exocarta.org/
query.html).
Following IL-12 stimulation, HPgV E2-positive EVs signiﬁcantly
inhibited IFNγ release by NK92 cells in a dose dependent manner
(Fig. 7A) compared to cells incubated in HPgV E2-negative,
Fc-positive control EVs. Thus E2 protein-containing EVs from
cell culture supernatant (Fig. 7A) inhibited IL-12-mediated
signaling in NK92 cells. Although the concentration of E2 protein
used in these in vitro studies is high, IFNγ release was also reduced
in cells incubated with HPgV positive serum (Fig. 1C and D),
suggesting that physiologically relevant amounts of E2 protein
present in serum or circulating virions suppress cytokine
responses.
HPgV E2 inhibits NK cell Tyk2 activation
To understand potential mechanisms by which HPgV E2
inhibited IL-12 R-mediated NK cell function, NK92MI cells were
incubated with HPgV positive or negative EVs overnight, and IL-12
mediated phosphorylation of STAT4, Janus Kinase 2 (Jak2), and
tyrosine kinase 2 (Tyk2) was assessed. Following IL-12 stimulation,
the membrane proximal kinases Tyk2 and Jak2 are activated
(phosphorylated) resulting in recruitment, phosphorylation, and
nuclear translocation of STAT4 leading to stimulation of cytokine
production (Babon et al., 2014). NK92 cells incubated with HPgV
E2 positive EVs demonstrated reduced phosphorylation of Tyk2
and STAT4 following IL12 stimulation compared to cells incubated
in control, Fc-containing EVs (Fig. 7B). HPgV E2 mediated IL-12
signaling inhibition was speciﬁc to Tyk2 phosphorylation, as JAK2
phosphorylation was not impaired (Fig. 7B).
Fig. 2. Gating strategy for intracellular staining of interferon gamma on NK cells. After gating on lymphocytes and single cells, CD3 negative and CD56 positive NK cells were
gated and intracellular interferon gamma analyzed following stimulation with either IL12 plus IL15 or PMA plus ionomycin or unstimulated. Representative plots of
responses to stimuli are shown.
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Bioinformatic analyses identiﬁed highly conserved motifs within
HPgV E2 that are predicted to serve as phosphorylation substrates
for Tyk2 (Xue et al., 2006). Consistent with this, incubation of
recombinant HPgV E2 and Tyk2 kinase resulted in the phosphor-
ylation of E2 in vitro (Fig. 6C), thus HPgV E2 may serve as a Tyk2
substrate. The motif on HPgV E2 predicted to serve as a Tyk2
substrate from isolates representing all 7 HPgV genotypes are
shown in Fig. 7D. FITC-labeled synthetic HPgV E2 peptides were
conjugated with the HIV TAT protein transduction domain (TAT) to
lead to peptide internalization. Following incubation with NK92
cells, the peptides were present intracellularly as shown by ﬂow
cytometry (Fig. 8A). The native HPgV E2 peptide (81-
SCPQYVYGSVSVT-93) signiﬁcantly inhibited IL-12-mediated IFNγ
production in the NK92 cell line, whereas substitution of an alanine
for either of the conserved tyrosines (Y85 or Y87), or both restored
IL-12 R signaling (Fig. 8B). The HPgV E2 peptides also inhibited IFNγ
in primary human NK cells following IL-12 stimulation when
compared to the Y85A or Y87A or AVA double mutant peptide
(Fig. 8C). Incubation of NK92 or primary human NK cells with the
native HPgV E2 peptide not conjugated to the TAT domain did not
alter IL-12 signaling (data not shown), thus peptide uptake by the
cells was required for the inhibition to occur.
Fig. 3. Extracellular vesicles (EVs) containing recombinant HPgV E2 protein inhibit
IL-12-mediated signaling and deliver E2 to NK cells. IFNγ release by the NK cell line
(NK92MI) following incubation with CHO cell culture supernatant EVs containing
recombinant HPgV E2-human Fc fusion protein or human Fc protein (A). Cells were
incubated 18 h prior to stimulation with IL-12 (p value for T test shown). E2-Fc and
Fc concentration used was 50 mg/ml. EVs from cell culture supernatant ﬂuids of
cells expressing HPgV E2-Fc contained E2, while EVs from CHO cells expressing just
Fc protein did not (B). NK92MI cells were incubated overnight with HPgV E2
positive EVs and the cells examined for surface or total cellular E2 protein following
permeabilization using ﬂow cytometry (C). The mean ﬂuorescence intensity (MFI)
of surface and total HPgV E2 in the cells is summarized in the graph (C).
Fig. 4. HPgV E2 positive extracellular vesicles (EVs) deliver E2 to NK cells. EVs
puriﬁed from cell culture supernatant ﬂuids of cells expressing HPgV E2-Fc protein
or the Fc-vector control were analyzed delivery of E2 to NK92MI cells. NK92MI cells
were incubated overnight with HPgV E2 positive EVs and the cells examined for
surface or total cellular E2 protein by ﬂow cytometry using antiE2 antibodies.
Representative data are shown.
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HPgV does not inhibit NK cell degranulation and cytolytic function
Since HPgV inhibited non-cytolytic NK cell function (IL-12
signaling), the effect of HPgV on NK cell cytolytic function was
assessed. PBMCs from HPgV positive and negative subjects were
incubated with K562 target cells, and cytolytic function was
measured by quantifying surface expression of CD107a on
CD56þ/CD3 NK cells by ﬂow cytometry or by measuring
granzyme B release from PBMCs into culture supernatant ﬂuids.
Representative gating from HPgV RNA positive and negative
subjects are shown in Fig. 9. There was no difference in
CD107a expression on primary NK cells obtained from HPgV
viremic or negative subjects (Fig. 10A). Furthermore, CD107a
expression was not altered on NK92 cells incubated with serum
(300 μl in 1 ml total volume) from HPgV viremic or uninfected
subjects prior to incubation with K562 target cells (Fig. 10B).
Similar to the CD107a results, there were no differences in the
amount of granzyme B released by PBMCs obtained from HPgV
viremic and uninfected subjects following incubation with K562
cells (Fig. 10C), or from NK92 cells incubated in serum from HPgV
infected or uninfected prior to the addition of K562 target cells
(Fig. 10D). Together these results demonstrate that HPgV serum
containing viral particles did not alter primary human PBMC or
NK92 cell killing (cytolytic) functions.
Materials and methods
Subjects
Following written informed consent, blood was obtained
from HIV infected subjects whose viral load (VL) was suppressed
(o48 copies/mL for Z6 months) by combination antiretroviral
therapy (cART), or from healthy blood donors. For HIV infected
subjects, HIV VL was tested on the day of blood sampling using
the COBASs AmpliPrep/COBASs TaqMans HIV-1 Test (Roche)
by the University of Iowa clinical laboratory as part of routine
medical care. HPgV-HIV co-infected subjects were selected
based on prior studies characterizing their HPgV status. The
study was approved by the University of Iowa Institutional
Review Board.
Cells and clinical samples
Serum was prepared and HPgV viral load determined as
previously described (Rydze et al., 2012; George et al., 2003).
PBMCs (2106 cells/ml) were prepared as previously described
(Lymphocyte Separation Media Mediatech, Manassas, VA) and
maintained in RPMI 1640 media containing 10% fetal bovine
serum, 25 U/ml recombinant human IL-2 (Zeptometrix), 10 mcg/
Fig. 5. Extracellular vesicles (EVs) deliver HPgV E2 protein to primary human NK cells. EVs released into cell culture supernatant from CHO cells expressing HPgV E2 protein
or control CHO cells were incubated with healthy donor peripheral blood mononuclear cells (PBMCs). PBMCs were gated as shown (A), and total cellular E2 uptake was
measured (B).
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mL phytohemagglutinin (PHA, Gibco) 100 U/ml penicillin, 100 U/
ml streptomycin, and 2 mM L-glutamine. Fifty percent of the media
was removed weekly and replaced with fresh media. Cells were
counted using the Countess™ automated cell counter (Invitrogen
Inc.). Viability was assessed using trypan blue exclusion. Serum
was treated with, or without UV inactivation (T8 Germicidal UV
lamp, GE) as indicated for 30 min prior to use.
A human NK cell line (NK92MI, ATCCs CRL2408™) was
cultured Alpha Minimum Essential Medium (Alpha-MEM) supple-
mented with 10% heat-inactivated Fetal Calf Serum, 5% horse
serum, 0.02 g/0.5 L Inositol, 0.005 g/0.5 L Folic acid, 909 ml/0.5 L
mercaptoethanol, 100 IU/ml Penicillin and 100 μg/ml streptomy-
cin. K562 cells were cultured in RPMI-1640 (GIBCO) supplemented
with 10% heat-inactivated Fetal Calf Serum, 2 mM L-glutamine,
100 IU/ml Penicillin and 100 μg/ml streptomycin.
NK cell functional assays
NK92MI cells were incubated with serum (300 μl) from HPgV
viremic and HPgV RNA-negative subjects, or with UV-treated
serum (as speciﬁed) for 6 h prior to overnight incubation with or
without IL-12 stimulation with (2 ng/ml; BD) in a total volume of
1 ml. IFN-γ was quantiﬁed in cell culture supernatants obtained
16 h later using the Human IFN-γ ELISA kit (BD Biosciences)
according to manufacturer's instructions. Alternatively,
intracellular IFN-γ was measured in primary peripheral blood NK
cells following stimulation with IL-12 (5 ng/ml; BD) and IL15 (5 ng/
ml; BD) or phorbol 12-myristate 13-acetate (PMA 50 ng/ml) and
Ionomycin (500 ng/ml) as speciﬁed. One hour after stimulation,
Brefeldin A (BFA; 10 μg/ml; Sigma) was added and after seven
hours, cells were harvested, ﬁxed and permeabilized (BD Cytoﬁx/
Cytoperm Solution, BD Biosciences) using the manufacturer's
instructions. IFN-γ in NK cells (CD3/CD56þ) was quantiﬁed by
ﬂow cytometry (BD LSR-II) and analyzed using FlowJo program
software (Tree Star). Antibodies used in these studies included:
CD3-V450, CD8-A700, CD56-PE, IFN-γ A647 (BD Biosciences). Data
was acquired on BD LSR II ﬂow cytometer using single stained
CompBeads (BD Biosciences) for compensation. At least 10,000
total events were collected in each experiment and the FlowJo
program (Tree Star Inc.) was used for data analysis.
Freshly isolated PBMCs (1106/ml) were co-cultured with
K562 target cells (1106/ml) for 5 h (37 1C) in the presence of
anti-CD107a-FITC (Southern BioTech). Degranulation was quanti-
ﬁed by measuring CD107a surface expression on CD56þ/CD3
NK cells (ﬂow cytometry) and granzyme B release in culture
supernatant (ELISA, Southern Biotech).
Phosphorylation of Tyk 2, Jak 2 or Stat 4 was measured in
peripheral blood NK cells following incubation with HPgV E2-Fc
positive or Fc-only extracellular vesicles (EVs) for 18 h followed by
IL 12 (5 ng/ml; BD) stimulation for 15 min. Cells were ﬁxed and
Fig. 6. Characterization of extracellular vesicles (EVs) containing HPgV E2 for exosomal markers. Gating of EVs used to deliver E2 to NK cells (A) were characterized for
exosomal markers by ﬂow cytometry. EVs were positive for cellular receptors CD69 and CD81 (B, C) but negative for CD69 (D).
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permeabilized (BD Cytoﬁx/Cytoperm) prior to staining in BD
permwash buffer. Antibodies used included: pJAK2 (Y1007/1008;
Cell Signaling), pTyk2 (Y1054/Y1055; BD), pSTAT4 (Y693; BD), goat
anti-rabbit FITC (Invitrogen), goat anti-mouse A647 (Invitrogen).
Viral proteins and extracellular vesicles preparation
HPgV E2-Fc protein (nt 1167-2161 based on GenBank AF 121950) or
the vector control expressing Fc were expressed in CHO S cell lines
previously described (McLinden et al., 2006). HPgV E2 was analyzed
by immunoblot using polyclonal rabbit anti-E2 peptide antibody using
chemiluminescence (Amersham ECL;GE Healthcare) as described
(McLinden et al., 2006; Bhattarai et al., 2012). CHO cells were
maintained in serum-free media in a bioreactor (CELLine CL1000;
Wilson Wolf) and supernatants were clariﬁed and exosomes puriﬁed
from supernatant using ExoQuick reagent (Systems Biosciences) as
recommended by the manufacturer. Isolated EVs were incubated with
aldehyde/sulfate latex beads (Invitrogen) at room temperature (RT).
After 1 h, 100 mL of glycine (100 mM) and 100 mL of BSA (10% w/v) was
added to the reaction and incubated for additional 30 min at RT. Beads
were washed in PBS (3 ) and pelleted by centrifugation for 2 min at
10,000g prior to ﬂow cytometry analysis. CD63, CD81 and CD69
monoclonal antibodies (BD Biosciences) were used to detect the
cognate molecules on exosomes using ﬂow cytometry.
FITC labeled synthetic HPgV E2 peptides with an N-terminal
HIV TAT protein transduction domain (TAT) alone (GGGGGRK
KRRQRRR), with wild type HPgV E2 aa 81–93 (GGGGGRKKRRQRR
RSCPQYVYGSVSVT), or mutants (AVA mutant GGGGGRKKRRQ
RRRSCPQAVAGSVSVT; AVY mutant (GGGGGRKKRRQRRRSCPQA-
VYGSVSVT; or YVA mutant GGGGGRKKRRQRRRSCPQYVAGSVSVT)
were purchased from EzBiolabs. PBMCs (1106 cells/ml) were
incubated with 50 mg of peptide at 37 1C for 3 h and subsequently
stimulated with 2 ng/ml IL-12 in the presence of BFA for 8 h.
Intracellular IFN-γ was quantiﬁed by ﬂow cytometry as
described above.
Recombinant E2 protein (40 mg) was incubated with or without
active human Tyk2 (250 ng) using an in vitro kinase assay as
recommended by the manufacturer (Signal Chem). Phosphoryla-
tion was determined by immunoblot analysis using phosphotyr-
osine antibodies (Invitrogen).
Statistics
Statistics and graphs were performed using GraphPad software
V5.0 (GraphPad Prism Software). Student's t test was used to
compare results between test and controls. P values less than 0.05
were considered statistically signiﬁcant.
Conclusions
HPgV and HCV are unusual among cytoplasmic human RNA
viruses in that they commonly cause persistent infection, thus
they have developed effective mechanisms to evade host immune
clearance. For HCV, several mechanisms are proposed to contri-
bute to immune evasion, including the presence of two
Fig. 7. HPgV envelope protein (E2) in extracellular vesicles inhibits IL-12 signaling pathways in NK cells. IFNγ released into NK92MI cell culture supernatants was inhibited
following incubation with a range of volumes of HPgV E2 positive or negative extracellular vesicles (EVs) prepared from CHO cell culture supernatants. EVs were quantiﬁed
by protein-A280 spectrometry. (A). IL-12-mediated signaling of healthy donor peripheral blood mononuclear cells following 18 h incubation with HPgV E2 positive or
negative EVs was assessed by intracellular pTyk2, pJak2 and pSTAT4 phosphorylation. HPgV E2 positive EVs inhibited Tyk2 and STAT4 but not Jak2 phosphorylation
compared to HPgV E2 negative EV controls (B). Tyk2 phosphorylated HPgV E2 protein in vitro as measured by anti-phosphotyrosine antibodies (C). Two tyrosine residues
within HPgV E2 protein (a.a. 85, 87) that are conserved among all 7 HPgV genotypes (representative sequences shown in D) were predicted to interact with a kinase (Tyk2)
required for IL-12 induced interferon induction *¼po0.05, **¼po0.01 (T test).
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hypervariable regions on the envelope (E2) protein, rapid muta-
tion of immunodominant T cell epitopes (Keck et al., 2014),
interference with intracellular signaling pathways resulting in
reduced innate and adaptive immune responses, and chronic
stimulation of T cells leading to T cell exhaustion (Burke and Cox,
2010; Lemon, 2010). In contrast, HPgV envelope proteins do not
have hypervariable regions, display limited sequence variability
within infected hosts, and HPgV infection is associated with
reduced T cell activation (Stapleton et al., 2012; Mohr and
Stapleton, 2009). Although the primary permissive cell type for
HPgV remains unclear, viral RNA is detected in several types of
peripheral blood cells including NK cells (Chivero et al., 2014),
suggesting that HPgV may modulate NK cell function.
In this study, NK cells from persistently infected people had
reduced IFNγ expression following IL-12 stimulation compared to
those without HPgV viremia. HPgV replication was not required
for inhibition, suggesting that components of HPgV particles
modulate NK cell function. Indeed, HPgV E2 glycoprotein was
sufﬁcient to inhibit IFNγ expression by NK cells, and an E2 protein
YVY-containing motif (amino acids 85–87) was required for
inhibition, as mutation of either tyrosine to alanine in the context
of these peptides restored IL-12 R-mediated induction of IFNγ. This
conserved motif is predicted to be a Tyk2 substrate, and Tyk2
phosphorylated HPgV E2 in vitro (Fig. 7C). The high VL observed in
HPgV infection (typically greater that 1107 genome copies/ml
plasma) (Tillmann et al., 2001) implies that interactions constantly
occur between NK cells and HPgV particles. Tyk2 activation is
required for IFNγ induction (Karaghiosoff et al., 2000; Shimoda
et al., 2002; Tokumasa et al., 2007), and Tyk2 deﬁcient mice are
unable to clear vaccinia virus and have reduced T cell responses
after LCMV challenge (Karaghiosoff et al., 2000). NK cell depletion
also enhances T-cell immunity leading to virus control preventing
chronic infection (Lang et al., 2012; Waggoner et al., 2014),
conﬁrming the important role NK cells play in chronic viral
infections. Our study highlights a potential role of NK cells in
contributing to chronic HPgV viremia. However, the absence of an
animal model makes it impossible to demonstrate NK cell deple-
tion or Tyk2 inhibition effects on HPgV persistence in vivo. The
current understanding of HPgV persistence and clearance mechan-
isms are shown in Fig. 11. The failure to detect antibody responses
to HPgV proteins and delayed development of E2 antibodies also
suggests impaired B cell function during HPgV infection. This, plus
the reduction in T cell and NK cell activation state during HIV
infection (Maidana-Giret et al., 2009; Stapleton et al., 2012, 2013;
Bhattarai et al., 2012) and as shown in these studies suggests a
modest HPgV-mediated effect resulting in global impairment of
cellular immune responses.
While interferonγ was decreased by HPgV in this study, direct
cytotoxicity measures (CD107a degranulation and granzyme B
release) were not altered, suggesting that HPgV selectively inter-
feres with the noncytoloytic functions of NK cells. In contrast, the
related virus HCV increases NK cell cytotoxicity (i.e. degranulation
and TNF-related apoptosis-inducing ligand; TRAIL) (Ahlenstiel
et al., 2010; Oliviero et al., 2009), potentially contributing to HCV
induced hepatocyte cell death, and conversely explaining in part
the lack of disease outcomes in HPgV infected hosts.
While HPgV is not associated with any acute or chronic
illnesses other than non-Hodgkin's lymphoma, its immunomodu-
latory capacity illustrates the complex relationships between viral
infection and host immune activation, particularly in HIV co-
infected subjects. HIV infection is associated with chronic immune
cell activation which is an important factor in HIV disease
progression, and immune activation enhances HIV replication
(Gonzalez et al., 2010; Sandberg et al., 2010; Nixon and Landay
2010; Giorgi et al., 1999). Immune activation is also associated
with immune dysfunction (Hazenberg et al., 2003) and reduced
responses to antiretroviral therapy (Hunt et al., 2003). Several
clinical studies found that among HIV-infected subjects HPgV
infection is associated with reduced T, B and NK cell activation
(Maidana-Giret et al., 2009; Stapleton et al., 2012; Bhattarai et al.,
2012), and HPgV infection acquired through blood transfusion is
associated with reduced proinﬂammatory cytokines compared to
controls in HIV co-infected subjects (Lanteri et al., 2014). The data
above show that HPgV viremia inhibits IL-12-mediated IFNγ
release by NK cells. Given the paracrine and pleomorphic effects
Fig. 8. Conserved tyrosine residues within HPgV envelope protein (E2) protein
were required for inhibition of IL-12 signaling in primary NK cells and NK cell lines.
Conserved tyrosine residues within HPgV E2 protein (a.a. 85, 87) predicted to
modulate Tyk2 kinase function were predicted to serve as a substrate for Tyk2.
NK92MI cells were incubated with no peptide or a FITC-labeled HPgV E2 peptide
containing the HIV TAT protein transduction domain (TAT). Peptide uptake is
shown by FITC ﬂuorescence (A). NK92MI cells (B) or peripheral blood mononuclear
cells (PBMCs; C) were incubated with the peptide vehicle (DMSO; PC), TAT peptide,
native HPgV peptide with TAT (TAT-YVY) or mutant TAT-HPgV peptides as indicated
for 6 h prior to IL12 stimulation (2 ng/ml). Following 18 h incubation, IFNγ was
quantiﬁed in cell culture supernatant by ELISA (B) or intracellularly gating on CD3-/
CD56þNK cells by ﬂow cytometry (C). Data represent cultures from three healthy,
HPgV negative independent blood donors. *¼po0.01 vs. DMSO and TAT only
peptide (T test). ***¼po0.01 vs. PC.
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of IFNγ, this inhibition likely contributes to reduced immunomo-
dulation and recruitment of cytotoxic CD8þ T cells, contributing
to a survival beneﬁt for the host. Consistent with this, a recent
study found a survival beneﬁt in Ebola infected subjects co-
infected with HPgV (Lauck et al., 2015). Ebola infection causes
hemorrhagic fever by inducing the release of pro-inﬂammatory
cytokines. It is tempting to speculate that the effect of HPgV
infection on cytokine induction in HIV disease contributes to a
survival beneﬁt with Ebola infection (Lauck et al., 2015), and may
alter outcomes in other immune-mediated disease states.
In summary, HPgV prolonged NK cell survival ex vivo, and
impaired noncytolytic function as exempliﬁed by IL-12-induced
IFNγ without inhibiting NK cytolytic function as measured by
granzyme B release and CD107a degranulation. HPgV E2 glycopro-
tein was sufﬁcient to inhibit IL-12-induced IFNγ expression in NK
cells through the inhibition of Tyk2 and STAT4 phosphorylation. We
show that HPgV E2 can be delivered to primary NK cells and the
NK92 cell line by EVs. Although beyond the scope of this investiga-
tion, further characterization of the mechanism of EV interactions
with cells is important. Speciﬁcally, EVs may enter target cells by
being taken up by the target cell endocytic pathway or by fusion
with the cell membrane with direct release of the EV contents into
the cytoplasm. This suggests that interference with NK cell function
may contribute to both the chronicity and high viral loads observed
in HPgV infection, and that these effects may contribute to the
reduced immune activation and proinﬂammatory cytokines
involved in the immunopathogenesis of HIV and other diseases.
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Fig. 11. Working model for HPgV persistence. Clinical studies show HPgV to be
associated with signiﬁcantly reduced expression of the activation marker CD69 on
NK cells, and activation markers CD38, CD69 and CD25 on CD4þ and CD8þ T cells.
Thus, HPgV infection is associated with reduced immune cell activation. In
addition, B cells usually do not mount an antibody response to HPgV proteins
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of viremia. Due to the impairment of both cellular and humoral immunity, HPgV
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this study, NK cells expressed less interferon gamma following IL-12 stimulation,
potentially contributing to dysfunctional immune regulation of CD8þ T cells.
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